DARE BIOSCIENCE INC. - COMMON STOCK

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

14 Aug 2025 13:01:00 By Nasdaq GlobeNewswire

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

07 Aug 2025 05:00:00 By Nasdaq GlobeNewswire

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

29 Jul 2025 05:00:00 By Nasdaq GlobeNewswire

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

21 Jul 2025 10:47:42 By Nasdaq GlobeNewswire

Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

21 Jul 2025 05:00:00 By Nasdaq GlobeNewswire

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

14 Jul 2025 05:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

11 Jul 2025 05:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

12 Jun 2025 14:00:00 By Nasdaq GlobeNewswire

Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream

04 Jun 2025 05:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

13 May 2025 13:01:00 By Nasdaq GlobeNewswire

Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025

06 May 2025 05:00:01 By Nasdaq GlobeNewswire

Daré Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women’s Health Innovation

23 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year

07 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

31 Mar 2025 13:01:00 By Nasdaq GlobeNewswire

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

24 Mar 2025 05:00:00 By Nasdaq GlobeNewswire

Daré Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant

20 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

06 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

09 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)

16 Dec 2024 05:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

10 Dec 2024 05:00:00 By Nasdaq GlobeNewswire